Literature DB >> 36008610

High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.

Brian R Shy1,2,3,4, Vivasvan S Vykunta5,6, Alvin Ha7,5,6, Alexis Talbot5,6,8,9,10, Theodore L Roth5,6,11, David N Nguyen5,6,12, Wolfgang G Pfeifer13,14, Yan Yi Chen5,6, Franziska Blaeschke5,6, Eric Shifrut5,6, Shane Vedova5,6, Murad R Mamedov5,6, Jing-Yi Jing Chung5,6,8,9, Hong Li15, Ruby Yu5,6, David Wu11, Jeffrey Wolf6,16, Thomas G Martin6,16, Carlos E Castro13,17, Lumeng Ye15, Jonathan H Esensten7,5, Justin Eyquem5,6,8,9, Alexander Marson18,19,20,21,22,23,24,25,26.   

Abstract

Enhancing CRISPR-mediated site-specific transgene insertion efficiency by homology-directed repair (HDR) using high concentrations of double-stranded DNA (dsDNA) with Cas9 target sequences (CTSs) can be toxic to primary cells. Here, we develop single-stranded DNA (ssDNA) HDR templates (HDRTs) incorporating CTSs with reduced toxicity that boost knock-in efficiency and yield by an average of around two- to threefold relative to dsDNA CTSs. Using small-molecule combinations that enhance HDR, we could further increase knock-in efficiencies by an additional roughly two- to threefold on average. Our method works across a variety of target loci, knock-in constructs and primary human cell types, reaching HDR efficiencies of >80-90%. We demonstrate application of this approach for both pathogenic gene variant modeling and gene-replacement strategies for IL2RA and CTLA4 mutations associated with Mendelian disorders. Finally, we develop a good manufacturing practice (GMP)-compatible process for nonviral chimeric antigen receptor-T cell manufacturing, with knock-in efficiencies (46-62%) and yields (>1.5 × 109 modified cells) exceeding those of conventional approaches.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2022        PMID: 36008610     DOI: 10.1038/s41587-022-01418-8

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   68.164


  39 in total

1.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Authors:  Haydar Frangoul; David Altshuler; M Domenica Cappellini; Yi-Shan Chen; Jennifer Domm; Brenda K Eustace; Juergen Foell; Josu de la Fuente; Stephan Grupp; Rupert Handgretinger; Tony W Ho; Antonis Kattamis; Andrew Kernytsky; Julie Lekstrom-Himes; Amanda M Li; Franco Locatelli; Markus Y Mapara; Mariane de Montalembert; Damiano Rondelli; Akshay Sharma; Sujit Sheth; Sandeep Soni; Martin H Steinberg; Donna Wall; Angela Yen; Selim Corbacioglu
Journal:  N Engl J Med       Date:  2020-12-05       Impact factor: 91.245

Review 2.  Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.

Authors:  Andrew V Anzalone; Luke W Koblan; David R Liu
Journal:  Nat Biotechnol       Date:  2020-06-22       Impact factor: 54.908

Review 3.  NextGen cell-based immunotherapies in cancer and other immune disorders.

Authors:  Camillia S Azimi; Qizhi Tang; Kole T Roybal; Jeffrey A Bluestone
Journal:  Curr Opin Immunol       Date:  2019-05-06       Impact factor: 7.486

4.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

Authors:  Justin Eyquem; Jorge Mansilla-Soto; Theodoros Giavridis; Sjoukje J C van der Stegen; Mohamad Hamieh; Kristen M Cunanan; Ashlesha Odak; Mithat Gönen; Michel Sadelain
Journal:  Nature       Date:  2017-02-22       Impact factor: 49.962

5.  Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.

Authors:  Judith Feucht; Jie Sun; Justin Eyquem; Yu-Jui Ho; Zeguo Zhao; Josef Leibold; Anton Dobrin; Annalisa Cabriolu; Mohamad Hamieh; Michel Sadelain
Journal:  Nat Med       Date:  2018-12-17       Impact factor: 53.440

6.  Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.

Authors:  David C Bishop; Leighton E Clancy; Renee Simms; Jane Burgess; Geetha Mathew; Leili Moezzi; Janine A Street; Gaurav Sutrave; Elissa Atkins; Helen M McGuire; Brian S Gloss; Koon Lee; Wei Jiang; Karen Maddock; Georgia McCaughan; Selmir Avdic; Vicki Antonenas; Tracey A O'Brien; Peter J Shaw; David O Irving; David J Gottlieb; Emily Blyth; Kenneth P Micklethwaite
Journal:  Blood       Date:  2021-10-21       Impact factor: 22.113

7.  CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells.

Authors:  M Goodwin; E Lee; U Lakshmanan; S Shipp; L Froessl; F Barzaghi; L Passerini; M Narula; A Sheikali; C M Lee; G Bao; C S Bauer; H K Miller; M Garcia-Lloret; M J Butte; A Bertaina; A Shah; M Pavel-Dinu; A Hendel; M Porteus; M G Roncarolo; R Bacchetta
Journal:  Sci Adv       Date:  2020-05-06       Impact factor: 14.136

8.  Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency.

Authors:  David N Nguyen; Theodore L Roth; P Jonathan Li; Peixin Amy Chen; Ryan Apathy; Murad R Mamedov; Linda T Vo; Victoria R Tobin; Daniel Goodman; Eric Shifrut; Jeffrey A Bluestone; Jennifer M Puck; Francis C Szoka; Alexander Marson
Journal:  Nat Biotechnol       Date:  2019-12-09       Impact factor: 54.908

9.  Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing.

Authors:  Andrew V Anzalone; Xin D Gao; Christopher J Podracky; Andrew T Nelson; Luke W Koblan; Aditya Raguram; Jonathan M Levy; Jaron A M Mercer; David R Liu
Journal:  Nat Biotechnol       Date:  2021-12-09       Impact factor: 68.164

10.  Reprogramming human T cell function and specificity with non-viral genome targeting.

Authors:  Theodore L Roth; Cristina Puig-Saus; Ruby Yu; Eric Shifrut; Julia Carnevale; P Jonathan Li; Joseph Hiatt; Justin Saco; Paige Krystofinski; Han Li; Victoria Tobin; David N Nguyen; Michael R Lee; Amy L Putnam; Andrea L Ferris; Jeff W Chen; Jean-Nicolas Schickel; Laurence Pellerin; David Carmody; Gorka Alkorta-Aranburu; Daniela Del Gaudio; Hiroyuki Matsumoto; Montse Morell; Ying Mao; Min Cho; Rolen M Quadros; Channabasavaiah B Gurumurthy; Baz Smith; Michael Haugwitz; Stephen H Hughes; Jonathan S Weissman; Kathrin Schumann; Jonathan H Esensten; Andrew P May; Alan Ashworth; Gary M Kupfer; Siri Atma W Greeley; Rosa Bacchetta; Eric Meffre; Maria Grazia Roncarolo; Neil Romberg; Kevan C Herold; Antoni Ribas; Manuel D Leonetti; Alexander Marson
Journal:  Nature       Date:  2018-07-11       Impact factor: 49.962

View more
  2 in total

Review 1.  The journey of CAR-T therapy in hematological malignancies.

Authors:  Junru Lu; Guan Jiang
Journal:  Mol Cancer       Date:  2022-10-08       Impact factor: 41.444

Review 2.  Selecting for CRISPR-Edited Knock-In Cells.

Authors:  Nina Reuven; Yosef Shaul
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.